New Two-Pronged attack on tough blood cancer
NCT ID NCT07003555
Summary
This early-stage study is testing the safety of a new type of cell therapy for people with multiple myeloma that has come back or stopped responding to other treatments and has spread outside the bone marrow. Doctors will give patients a one-time infusion of specially engineered immune cells designed to target two proteins on the cancer cells. The main goal is to see what side effects occur and how severe they are in the first month after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Liquan Hospital
RECRUITINGShanghai, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.